Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-06 · accession 0001799191-25-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-07 | 2025-01-06 | STLN | Carter Robert Ross | CFO | D - Sale to Iss | $0.34 | -258 | 31.5K | -0.8% | -$87.72 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-01-06 | D | D | 258 | $0.34 | 31,501 | D | — | — | (F1) The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. (F2) Price is the volume weighted average selling price of all sales by the Reporting Person on January 6, 2025 within a one-dollar range. Actual prices ranged from $0.293 to $0.335. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |